n COVID-19 patients, disruption of the CCL5-CCR5 axis through CCR5 blocking antibody leronlimab was shown to reduce plasma IL-6, and SARS-CoV-2 plasma viremia [34]. For that reason, leronlimab is currently under investigation in a Phase2b/3 for severely ill COVID-19 patients [35]. Interestingly, the CCR5 Δ32 allele was found to be an important genetic marker of SARS-CoV-2 related death [36].